{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:53:46Z","timestamp":1791330826878,"version":"4.3.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cllc.2026.08.009","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:04:46Z","timestamp":1787814286000},"page":"11-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness of First-Line Tyrosine Kinase Inhibitors in ALK-Positive Metastatic Non\u2013Small Cell Lung Cancer by Presence of Brain Metastases"],"prefix":"10.1016","volume":"27","author":[{"given":"Sharmistha","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5249-8904","authenticated-orcid":false,"given":"Hoa H.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajibade","family":"Ashaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Danes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Roney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci","family":"LeMasters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Chirikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.08.009_bib0001","unstructured":"Key Statistics for Lung Cancer: American Cancer Society; 2026 Accessed March 31, 2026. https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/key-statistics.html."},{"key":"10.1016\/j.cllc.2026.08.009_bib0002","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CLEP.S69718","article-title":"Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors","volume":"6","author":"Chia","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"26","key":"10.1016\/j.cllc.2026.08.009_bib0003","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.009_bib0004","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2026.08.009_bib0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.lungcan.2006.10.001","article-title":"Distress screening in a multidisciplinary lung cancer clinic: prevalence and predictors of clinically significant distress","volume":"55","author":"Graves","year":"2007","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.009_bib0006","doi-asserted-by":"crossref","DOI":"10.2217\/lmt-2020-0018","article-title":"Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform","volume":"10","author":"Lin","year":"2020","journal-title":"Lung Cancer Manag"},{"key":"10.1016\/j.cllc.2026.08.009_bib0007","doi-asserted-by":"crossref","first-page":"12104","DOI":"10.1200\/JCO.2024.42.16_suppl.12104","article-title":"Young lung cancer: psychosocial needs assessment","volume":"42","author":"Florez","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2026.08.009_bib0008","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/humupd\/dmz027","article-title":"Ovarian damage from chemotherapy and current approaches to its protection","volume":"25","author":"Spears","year":"2019","journal-title":"Hum Reprod Update"},{"issue":"6","key":"10.1016\/j.cllc.2026.08.009_bib0009","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1200\/JCO.23.01390","article-title":"Sexual health in adolescents and young adults with cancer","volume":"42","author":"Cherven","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2026.08.009_bib0010","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.fertnstert.2009.03.068","article-title":"Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis","volume":"94","author":"Chatzidarellis","year":"2010","journal-title":"Fertil Steril"},{"issue":"30","key":"10.1016\/j.cllc.2026.08.009_bib0011","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1200\/JCO.2012.41.7915","article-title":"Sexuality in adult cancer survivors: challenges and intervention","volume":"30","author":"Bober","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2026.08.009_bib0012","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2026.08.009_bib0013","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2026.08.009_bib0014","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.cllc.2026.08.009_bib0015","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cllc.2026.08.009_bib0016","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cllc.2026.08.009_bib0017","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cllc.2026.08.009_bib0018","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.08.009_bib0019","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2147\/DDDT.S19045","article-title":"Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond","volume":"5","author":"Ou","year":"2011","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"10.1016\/j.cllc.2026.08.009_bib0020","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs Crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2026.08.009_bib0021","doi-asserted-by":"crossref","first-page":"369","DOI":"10.21037\/tlcr-22-656","article-title":"Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer-a narrative review","volume":"12","author":"Chazan","year":"2023","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.009_bib0022","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cllc.2022.09.007","article-title":"Real-world treatment sequencing, toxicities, health utilities, and survival outcomes in patients with advanced ALK-rearranged non-small-cell lung cancer","volume":"24","author":"Schmid","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"11_suppl","key":"10.1016\/j.cllc.2026.08.009_bib0023","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/OP.2023.19.11_suppl.535","article-title":"Real-world tolerability of front-line brigatinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) with and without brain metastases in the United States","volume":"19","author":"Tai","year":"2023","journal-title":"JCO Oncology Practice"},{"key":"10.1016\/j.cllc.2026.08.009_bib0024","unstructured":"Komodo Healthcare Map: Komodo Health, Inc.; Available from: https:\/\/www.komodohealth.com\/solutions\/healthcare-map\/accessed (2026). Accessed March 31, 2026."},{"issue":"9","key":"10.1016\/j.cllc.2026.08.009_bib0025","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/oncolo\/oyac116","article-title":"Real-world efficacy and tolerability of brigatinib in patients with non-small cell lung cancer with prior ALK-TKIs in the United States","volume":"27","author":"Jahanzeb","year":"2022","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.009_bib0026","doi-asserted-by":"crossref","DOI":"10.2196\/29017","article-title":"An automated line-of-therapy algorithm for adults with metastatic non-small cell lung cancer: validation study using blinded manual chart review","volume":"9","author":"Meng","year":"2021","journal-title":"JMIR Med Inform"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.009_bib0027","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"issue":"28","key":"10.1016\/j.cllc.2026.08.009_bib0028","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.cllc.2026.08.009_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251316200","article-title":"Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements","volume":"17","author":"Kim","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2026.08.009_bib0030","first-page":"890","article-title":"Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"31","author":"Mudumba","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"issue":"Supplement 1","key":"10.1016\/j.cllc.2026.08.009_bib0031","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/blood-2023-189506","article-title":"Comparison of the efficacy in clinical trials versus effectiveness in the real-world of treatments for multiple myeloma: a population-based cohort study","volume":"142","author":"Visram","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cllc.2026.08.009_bib0032","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/cncr.32697","article-title":"Assessing the efficacy-effectiveness gap for cancer therapies: a comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics","volume":"126","author":"Phillips","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2026.08.009_bib0033","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41591-024-03352-5","article-title":"Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations","volume":"31","author":"Orcutt","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.cllc.2026.08.009_bib0034","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13909","article-title":"Exploring the discrepancies between clinical trials and real-world data: a small-cell lung cancer study","volume":"17","author":"Marzano","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.cllc.2026.08.009_bib0035","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cllc.2024.08.003","article-title":"Comparative efficacy and safety of lorlatinib versus alectinib and lorlatinib versus brigatinib for ALK-positive advanced\/metastatic NSCLC: matching-adjusted indirect comparisons","volume":"25","author":"Garcia","year":"2024","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.009_bib0036","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/07853890.2023.2187077","article-title":"Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients","volume":"55","author":"Gil","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.cllc.2026.08.009_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107319","article-title":"Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: systematic review and network meta-analysis","volume":"184","author":"Luo","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.08.009_bib0038","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.annonc.2026.05.692","article-title":"Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study","volume":"37","author":"Shaw","year":"2026","journal-title":"Ann Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:40:34Z","timestamp":1791330034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426001130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1525730426001130"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.009","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Effectiveness of First-Line Tyrosine Kinase Inhibitors in ALK-Positive Metastatic Non\u2013Small Cell Lung Cancer by Presence of Brain Metastases","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Takeda Development Center Americas, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}